Head and neck squamous cell carcinoma
By Daniel E. Johnson, B. Burtness, C. Leemans, V. Lui, J. Bauman, J. Grandis. Nature Reviews Disease Primers, 2020
1,651 citations recorded by the source corpus.
Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC). Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16. Thus, HNSCC can be separated into HPV-negative and HPV-positive HNSCC. Despite evidence of histological progression from cellular atypia through various degrees of dysplasia, ultimately leading to invasive HNSCC, most patients are diagnosed with late-stage HNSCC without a clinically evident antecedent pre-malignant lesion. Traditional staging of HNSCC using the tumour–node–metastasis system has been supplemented by the 2017 AJCC/UICC staging system, which incorporates additional information relevant to HPV-positive disease. Treatment is generally multimodal, consisting of surgery followed by chemoradiotherapy (CRT) for oral cavity cancers and primary CRT for pharynx and larynx cancers. The EGFR monoclonal antibody cetuximab is generally used in combination with radiation in HPV-negative HNSCC where comorbidities prevent the use of cytotoxic chemotherapy. The FDA approved the immune checkpoint inhibitors pembrolizumab and nivolumab for treatment of recurrent or metastatic HNSCC and pembrolizumab as primary treatment for unresectable disease. Elucidation of the molecular genetic landscape of HNSCC over the past decade has revealed new opportunities for therapeutic intervention. Ongoing efforts aim to integrate our understanding of HNSCC biology and immunobiology to identify predictive biomarkers that will enable delivery of the most effective, least-toxic therapies. Head and neck squamous cell carcinomas (HNSCCs) originate from the mucosal epithelium in the oral cavity, pharynx and larynx and are commonly associated with viral infection and tobacco use. This Primer provides an overview of the epidemiology, pathogenesis and treatment of HNSCCs of different aetiologies and the effects of the cancer and its treatment on patient quality of life.
Subfields: Oncology, Otorhinolaryngology, Surgery
View Paper: https://www.semanticscholar.org/paper/82264a40ede178d1970db66c3d004a8f52cecf2b
Citations in the corpus
- Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “Over decades, the prognosis of HNSCC patients has not significantly improved, with the five-year overall survival rate persisting at 50–60% [3].”
- Vitamin D and Clinical Outcomes in Head and Neck Cancer: A Systematic Review (2025, unknown): “Head and neck cancers (HNCs) encompass a heterogeneous group of malignancies originating in the oral cavity, pharynx, larynx, nasal cavity, and salivary glands, with squamous cell carcinoma (SCC) predominating, particularly in the oral cavity [14,15].”